Pitobrutinib mechanism of action

Pirtobrutinib (Pirtobrutinib, trade name Jaypirca, is a new targeted therapy drug developed by Eli Lilly and Company. It is mainly used to treat relapsed or refractory mantle cell lymphoma (MCL) and other types of B-cell lymphoma after multiple treatments (including BTK inhibitors). Its unique non-covalent binding mechanism makes pitobrutinib show great potential in the treatment of B-cell cancers.

Bruton's tyrosine kinase (BTK) is a key molecule in the B cell receptor signaling pathway and is essential for the development, function, adhesion and migration of B cells. In B cells, BTK is involved in activating B cell antigen receptor (BCR) signaling and cytokine receptor pathways. Abnormal activation of these pathways is often closely related to the occurrence and development of B cell cancers. Therefore, inhibiting BTK activity has become an important strategy for treating B cell cancers.

The mechanism of action of pitobrutinib is based on this target. It binds to BTK in a non-covalent manner and inhibits its activity, thereby blocking the BTK-mediated signaling pathway and inhibiting the proliferation and survival of malignant B cells. Compared with other covalent BTK inhibitors, pitobrutinib is unique in that it does not rely on covalent binding to the active site of BTK. Even in the presence of mutations in the BTK active site (such as Cys481 mutations), pitobrutinib can still maintain its inhibitory activity, which provides a new idea for solving the problem of resistance to BTK inhibitors.

In non-clinical studies, pitobrutinib has demonstrated significant inhibitionBTK-mediated B cell CD69 expression and malignant B cell proliferation. These research results provide strong support for the application of pitobrutinib in clinical treatment.

The launch of Pitobrutinib brings a new treatment option for patients with B-cell cancers, especially those who have responded poorly to or relapsed with traditional treatment options. Its unique non-covalent binding mechanism and good preclinical research results give pitobrutinib broad application prospects in the field of B cell cancer treatment.

xa0

Reference materials:https://go.drugbank.com/drugs/DB17472